Skip to main content
Skip to navigation
Research Exchange
Living Lab
Discovery Lab
Donate
Letter Re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according To BRCA1/2 mutation type and site: a multicenter real-world study
A.H. Önder & M.M. Çatlı
· 2025
Links
DOI
Journal
Unknown Journal
Authors
A.H. Önder
,
M.M. Çatlı